ArticleClinical rheumatology2026
Exaggerated axial osteoproliferation in patients with spondyloarthritis accompanying chronic kidney disease.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAxial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by entheseal inflammation, pathological new bone formation and structural lesions on spinal radiography. Chronic kidney disease (CKD) especially in its moderate to advanced stages manifests with abnormalities such as secondary hyperparathyroidism, renal osteodystrophy and vascular or ligamentous calcifications. This study aimed to compare radiographic spinal abnormalities in axSpA patients with CKD, axSpA patients without CKD, and CKD patients without inflammatory arthritis.
methodsThis retrospective study used data from the HURBIO registry, including 3207 bDMARD-treated patients with spondyloarthritis (SpA). Patients with axSpA and CKD (axSpA-CKD group, n = 28, 0.87% of the cohort) were compared with 56 age- and sex-matched axSpA patients without CKD (axSpA-nonCKD group) and 38 CKD patients without SpA (non-SpA CKD group). Cervical/lumbar and pelvic radiographs were evaluated for vertebral erosion, squaring, sclerosis, syndesmophyte (any), bamboo spine, and mSASSS scores.
resultsThe prevalence of syndesmophytes was significantly higher in axSpA-CKD patients compared with axSpA-nonCKD patients (64.2% vs. 25.0%, p = 0.002). Syndesmophyte-like osteoproliferative changes in the axial spine were observed in eight (21.0%) non-SpA CKD patients. Higher total mSASSS scores were independently associated with the presence of CKD (β = 18.5, 95% CI 9.03-28.06, p < 0.001), independent of age at bDMARD initiation, sex, disease duration, smoking, and HLA-B27 positivity, and this association remained significant after further adjustment for BASDAI scores as well as for the presence of amyloidosis and uveitis (all models, p ≤ 0.017).
conclusionThe results suggest that enthesial changes in the axial spine are more frequent and severe in axSpA patients with CKD compared to matched axSpA patients without CKD. In patients with axSpA-CKD, the contribution of CKD to new bone formation should be considered in the evaluation of radiographic damage.
Indexed as
Identifiers
42752763What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.